Several MAPK pathway inhibitors have been approved by the US Food and Drug Administration (FDA) for the treatment of clinical melanoma, including BRAF and MEK kinase inhibitors, which are poorly tolerated and are prone to development of resistance during treatment [128]. Here, MAP2K7 is linked to melanoma.